Eagle Pharmaceuticals Inc. appointed David Pernock president and chief commercial officer, effective January 2017.
Pernock, who will report to CEO Scott Tarriff, will oversee all commercial strategy and execution for Eagle's product portfolio.
Pernock most recently was the CEO of gene therapy biotechnology company Fibrocell Science and previously was GlaxoSmithKline plc's senior vice president of pharmaceuticals, vaccines, oncology, acute care and HIV divisions.
Pernock has been serving Eagle Pharmaceuticals as a director since April 2015. He will give up this position when his new role takes effect.